Breast Cancer Diagnosis: Tests, Mammography, Ultrasound, Biopsy and Staging Explained

Hearing that a breast examination or mammogram is abnormal can be frightening. An abnormal finding does not automatically mean cancer. Lumps, pain, discharge and appearance changes can come from cysts, fibroadenomas, hormonal shifts or other benign conditions — or they may need further investigation.

Doctors typically use triple assessment: clinical breast examination, breast imaging and pathological examination when indicated. A breast cancer diagnosis is generally confirmed through biopsy, where tissue is examined under a microscope.

This guide covers mammography, ultrasound, MRI, biopsy, BI-RADS, ER/PR/HER2 testing, staging and what international patients should know about diagnosis pathways in India. Companion reading: breast cancer symptoms, diagnosis tests (biopsy & receptors), stages, treatment options and treatment cost in India.

After diagnosis, treatment planning may involve surgery, chemotherapy, radiation, hormone therapy or targeted drugs. GAF planning for lumpectomy is $3,500–$8,000 (typically 1–3 nights) and for mastectomy is $4,500–$10,000 (typically 3–6 nights). Neighbouring sentinel lymph node biopsy is $2,000–$5,500. These are partner planning ranges, not quotations.

Patients comparing surgical oncologists often start with lumpectomy and mastectomy lists alongside medical oncology. Partner hospitals in Delhi NCR, Mumbai and Bengaluru are a typical first filter — see the international patients guide.

Diagnosis determines whether a breast abnormality is cancerous and characterises the tumour so the team can plan care. Key questions include:

Triple assessment is the standard way to investigate suspicious breast symptoms. The three components complement each other; disagreement between exam, imaging and biopsy prompts further review. National standard treatment guidance in India also emphasises this approach.

Example: a palpable lump that looks suspicious on ultrasound may lead to image-guided core needle biopsy. Relying on a single test increases the chance of missing or misinterpreting disease.

A breast specialist or trained clinician examines both breasts and regional nodes. They assess size and shape, lump location and feel, skin changes, nipple position or discharge, armpit swelling and nodes near the collarbone. History covers onset, growth, pain, menstrual and reproductive factors, prior breast disease, family history and previous imaging or biopsy.

Examination can flag suspicion but cannot confirm cancer alone. Imaging and tissue testing may still be required — especially when symptoms match patterns described in the symptoms guide.

Mammography uses low-dose X-rays to image breast tissue. It can show small masses, microcalcifications, architectural distortion and other changes that are not obvious on exam.

Compression may feel briefly uncomfortable and usually lasts only a few minutes. It improves image quality and can reduce the radiation needed.

A new breast lump generally needs diagnostic assessment rather than waiting for the next routine screen. Three-dimensional mammography (tomosynthesis) captures multiple angles and may help when overlapping tissue is hard to interpret; availability varies.

Ultrasound uses sound waves to examine palpable lumps or mammographic abnormalities. It helps distinguish fluid-filled cysts from solid masses, map lump location, assess nodes and guide biopsy. The exam is usually painless and uses no ionising radiation.

Ultrasound and mammography are complementary — one does not universally replace the other. Age, breast density, symptoms and findings decide the mix.

Breast MRI uses magnetic fields and radio waves, often with gadolinium contrast, for detailed images. It is not required for every lump. Doctors may use it to assess extent of known cancer, evaluate possible multifocal disease or invasive lobular carcinoma, screen selected high-risk women, clarify inconclusive conventional imaging, check response to neoadjuvant therapy or assess some implant cases.

Patients lie face down in a dedicated breast coil; exams often take about 30–60 minutes. MRI is highly sensitive but can also flag non-cancerous findings that need extra work-up — so teams choose it for specific clinical reasons.

A biopsy removes a small sample of tissue or cells for laboratory examination. It is generally the definitive way to confirm whether a suspicious area is cancerous. Imaging can look suspicious without proving cancer.

Core needle biopsy is commonly preferred because it preserves tissue architecture for type, grade and biomarkers. Image-guided approaches include ultrasound-, stereotactic/mammography- and MRI-guided biopsy when the target cannot be felt.

Most needle biopsies use local anaesthesia. Patients may feel the anaesthetic injection, pressure, temporary bruising or mild tenderness. A marker clip may be placed for later surgery or imaging. Procedures often take about 15–45 minutes as outpatient care.

A pathologist prepares a histopathology report — one of the most important documents in the pathway. It may show a benign finding, a pre-cancerous change or cancer. If cancer is confirmed, the report typically covers type, invasion, grade and receptors. Full walkthrough: pathology report explained.

Diagnosis is incomplete without tumour biology. Oestrogen receptor (ER), progesterone receptor (PR) and HER2 status help select hormone therapy, HER2-targeted treatment or other systemic pathways.

Triple-negative breast cancer is ER-, PR- and HER2-negative by testing criteria. Chemotherapy (± immunotherapy in eligible cases) often plays a larger role. Deeper detail: ER/PR/HER2 guide and diagnosis tests blog.

When HER2 IHC is equivocal, in-situ hybridisation (ISH) may be added. Both histopathology and IHC feed the multidisciplinary plan.

BI-RADS (Breast Imaging Reporting and Data System) standardises how radiologists describe mammography, ultrasound and MRI findings.

BI-RADS 4 does not mean cancer — it means the finding is suspicious enough for biopsy. BI-RADS 5 is highly suggestive of malignancy, but tissue diagnosis is still required. BI-RADS 3 is probably benign; attend the recommended short-interval follow-up.

After confirmation, staging describes how far disease has spread using the TNM system, often combined with grade and biomarkers for prognostic staging. Overview: breast cancer stages and stages 0–4.

Metastatic (Stage IV) disease has spread beyond the breast and regional nodes — commonly to bone, liver, lung or brain. Treatment then focuses on disease control and quality of life alongside biology-specific therapy. See treatment by stage.

Not every patient needs whole-body scanning. Extra tests depend on clinical stage, symptoms and risk.

PET-CT is not compulsory for every early-stage case. Unnecessary scans can find unrelated findings that drive anxiety and extra procedures — teams order staging studies based on need.

The sentinel node is the first drainage node (or group) from the tumour area. Surgeons inject a tracer (radioisotope, blue dye or both), remove the identified node(s) and send them for pathology.

A positive node does not automatically mean full axillary clearance; modern decisions are individualised. GAF planning for sentinel lymph node biopsy is $2,000–$5,500 (typically 1–2 nights). Surgery context: breast cancer surgery in India.

The full journey may take several days to a few weeks. Ask when each report is due and whether a multidisciplinary board will review results.

Confirmation starts treatment planning. A multidisciplinary team may include surgical, medical and radiation oncologists, radiologists, pathologists, reconstructive surgeons and oncology nurses.

Care may begin with surgery or with medicines first (neoadjuvant therapy / neoadjuvant chemotherapy). Pathways: treatment options, chemotherapy, adjuvant chemotherapy, radiation and reconstruction / reconstruction treatment.

Indian centres offer specialist consultation, mammography, ultrasound, MRI, image-guided biopsy, histopathology and biomarker testing. Patients from East Africa, the Middle East and elsewhere often combine diagnosis review with second opinions and treatment planning.

GAF Healthcare can help identify hospitals, coordinate appointments, arrange record review and estimates, and support travel logistics — see international patients.

Do not delay necessary treatment only to repeat every test abroad. Let the receiving specialist decide what must be redone.

Diagnostic packages vary by hospital, city, imaging mix, biopsy method and pathology panel. GAF does not publish standalone mammography or ultrasound package prices — request a written hospital estimate for the investigations your specialist recommends.

Once a treatment pathway is clear, use named GAF cost sheets for surgery and systemic care. Full context: breast cancer treatment cost in India.

Do not sum every line into one total. Targeted therapy and immunotherapy depend on medicine and duration.

Usually through clinical examination, imaging such as mammography and ultrasound, and a biopsy. Tissue examined under a microscope confirms whether cancer is present.

A breast biopsy with histopathology is generally definitive. Imaging identifies suspicious areas but cannot always confirm cancer.

No. Mammography detects suspicious changes; ultrasound, MRI and biopsy may still be required.

Mammography uses low-dose X-rays and is strong for microcalcifications. Ultrasound uses sound waves and helps distinguish cysts from solid masses.

No. MRI is used selectively — for example high-risk screening, extent assessment or inconclusive conventional imaging.

No. Biopsy investigates an abnormality. Results may be benign, pre-cancerous or cancerous.

Core needle biopsy usually provides tissue architecture and is commonly preferred for suspected breast cancer. FNA has selected uses for cells or fluid.

Histopathology often takes several working days. IHC and other tests may add more time depending on the laboratory.

BI-RADS 4 means a suspicious imaging abnormality. Biopsy is generally recommended — it does not by itself confirm cancer.

BI-RADS 5 means imaging is highly suggestive of malignancy. Tissue confirmation is still required.

ER-positive cancers express oestrogen receptors; HER2-positive cancers have increased HER2 expression or amplification. These results guide treatment — see the biomarker guide.

No. PET-CT is selective, especially when advanced disease is suspected. It is not routine for every early-stage case.

No routine blood test independently confirms breast cancer. Tissue examination is generally required.

Yes. Persistent symptoms or a suspicious exam may need further imaging or biopsy even after a normal mammogram.

Doctors may recommend repeat image-guided biopsy, additional imaging or surgical biopsy after reviewing clinical, imaging and pathology findings together.

Yes. Screening can find some cancers before symptoms. Early diagnosis helps teams consider treatment while disease is more limited.

Yes. Many hospitals offer mammography, ultrasound, MRI, biopsy, histopathology and biomarker testing. Facilities vary — see breast cancer treatment in India.

A second opinion can help review biopsy findings, biomarkers, stage and treatment options, especially for complex decisions.

Accurate diagnosis is the foundation of treatment. GAF Healthcare helps international patients coordinate records, specialist consultations and estimates for breast cancer care in India. Website: https://gaf.healthcare/.

This article is for general educational purposes and does not replace consultation, diagnosis or treatment advice from a qualified professional. Diagnostic tests must be selected by a clinician based on individual findings. Cost figures are indicative planning ranges for named pathways. Emergency symptoms belong in a local emergency department.